BR112012027143A2 - enzima da doença do armazenamento lisossomal - Google Patents

enzima da doença do armazenamento lisossomal

Info

Publication number
BR112012027143A2
BR112012027143A2 BR112012027143A BR112012027143A BR112012027143A2 BR 112012027143 A2 BR112012027143 A2 BR 112012027143A2 BR 112012027143 A BR112012027143 A BR 112012027143A BR 112012027143 A BR112012027143 A BR 112012027143A BR 112012027143 A2 BR112012027143 A2 BR 112012027143A2
Authority
BR
Brazil
Prior art keywords
storage disease
acid lipase
lysosomal storage
disease enzyme
lysosomal acid
Prior art date
Application number
BR112012027143A
Other languages
English (en)
Other versions
BR112012027143B1 (pt
BR112012027143A8 (pt
Inventor
Alex J Harvey
Anthony Quinn
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of BR112012027143A2 publication Critical patent/BR112012027143A2/pt
Publication of BR112012027143A8 publication Critical patent/BR112012027143A8/pt
Publication of BR112012027143B1 publication Critical patent/BR112012027143B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)

Abstract

enzima da doença do armazenamento lisossonal. a presente invenção refere-se a composições de lipase ácida lisossomal humana recombinante possuindo padrões de glicosilação específicos para internalização em células-alvo, um vetor contendo o ácido nucleio que condifica a lipase ácida lisossomal humana, uma célula hospedeira transformada com o vetor, composições farmacêuticas compreendendo a lipase ácida lisossomal humana recombinante e um método de tratamento de condições associadas com a deficiência de lipase ácida lisossomal.
BR112012027143-1A 2010-04-23 2011-04-23 Glicoproteínas de lipase ácida lisossomal recombinante humana isolada e composições farmacêuticas compreendendo as mesmas BR112012027143B1 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US34317710P 2010-04-23 2010-04-23
US61343177 2010-04-23
US39637610P 2010-05-26 2010-05-26
US61396376 2010-05-26
US40301110P 2010-09-09 2010-09-09
US61403011 2010-09-09
US45601410P 2010-10-29 2010-10-29
US61456014 2010-10-29
US201161432372P 2011-01-13 2011-01-13
US61432372 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme

Publications (3)

Publication Number Publication Date
BR112012027143A2 true BR112012027143A2 (pt) 2016-11-16
BR112012027143A8 BR112012027143A8 (pt) 2017-09-19
BR112012027143B1 BR112012027143B1 (pt) 2020-02-11

Family

ID=44834852

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027143-1A BR112012027143B1 (pt) 2010-04-23 2011-04-23 Glicoproteínas de lipase ácida lisossomal recombinante humana isolada e composições farmacêuticas compreendendo as mesmas

Country Status (21)

Country Link
US (4) US20130209436A1 (pt)
EP (3) EP4241854A3 (pt)
JP (4) JP5925187B2 (pt)
KR (1) KR101742346B1 (pt)
CN (2) CN102985538B (pt)
AU (1) AU2011242461B2 (pt)
BR (1) BR112012027143B1 (pt)
CA (2) CA2796607C (pt)
DK (2) DK2561069T3 (pt)
ES (2) ES2627535T3 (pt)
FI (1) FI3205351T3 (pt)
HK (2) HK1183059A1 (pt)
HU (2) HUE033217T2 (pt)
IL (2) IL222513A0 (pt)
LT (1) LT3205351T (pt)
MX (2) MX338426B (pt)
PL (2) PL2561069T3 (pt)
PT (2) PT2561069T (pt)
RU (2) RU2015151189A (pt)
SI (2) SI2561069T1 (pt)
WO (1) WO2011133960A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE429927T1 (de) 2000-02-04 2009-05-15 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US20080064862A1 (en) * 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
KR101742346B1 (ko) 2010-04-23 2017-06-15 시나게바 바이오파르마, 코포레이션 리소솜 축적병 효소
AR082953A1 (es) 2010-09-09 2013-01-23 Synageva Biopharma Corp Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes
EP2675472A4 (en) * 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
WO2013131014A1 (en) * 2012-03-02 2013-09-06 Synageva Biopharma Corp. Truncated lysosomal acid lipase
BR112016024586B1 (pt) * 2014-04-23 2022-03-29 Alexion Pharmaceuticals, Inc Método de preparação de clara de ovo para o processamento cromatográfico em massa
EP3472352A1 (en) 2016-06-17 2019-04-24 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
WO2018039163A1 (en) 2016-08-23 2018-03-01 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
WO2018064303A1 (en) 2016-09-30 2018-04-05 Alexion Pharmaceuticals, Inc. Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
WO2019152343A1 (en) 2018-02-01 2019-08-08 Alexion Pharmaceuticals, Inc. Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal
AU2020298575A1 (en) * 2019-07-02 2022-02-24 M6P Therapeutics (Switzerland) GmbH Vector compositions and methods of using same for treatment of lysosomal storage disorders
CN114369620B (zh) * 2021-12-31 2024-05-24 广州博垚生物科技有限公司 一种可持续分泌lal的载体、脐带间充质干细胞及其构建方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU3275595A (en) 1994-08-05 1996-03-04 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
CA2265464C (en) 1996-09-13 2007-06-26 Transkaryotic Therapies, Inc. Therapy for .alpha.-galactosidase a deficiency
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
CA2305768A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
JP4990434B2 (ja) 1998-12-07 2012-08-01 ジェンザイム・コーポレーション ポンペ病の処置
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
ATE429927T1 (de) 2000-02-04 2009-05-15 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002221755A1 (en) 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6387680B1 (en) * 2001-03-29 2002-05-14 Pe Corporation (Ny) Isolated human lipase proteins, nucleic acid molecules encoding human lipase proteins, and uses thereof
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
CA2474807A1 (en) 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
EP1495328B1 (en) 2002-04-16 2014-06-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A marker for measuring liver cirrhosis
AU2003283976B2 (en) 2002-09-27 2009-12-10 Cold Spring Harbor Laboratory Cell-based RNA interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
EP1784203B1 (en) 2004-08-19 2010-06-30 Biogen Idec MA Inc. Refolding transforming growth factor beta family proteins
US20080064862A1 (en) 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US8124732B2 (en) 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
ES2744125T3 (es) 2005-10-05 2020-02-21 Alexion Pharma Inc Producción rápida de virus de título elevado
AU2006304856A1 (en) 2005-10-21 2007-04-26 Synageva Biopharma Corp. Glycolated and glycosylated poultry derived therapeutic proteins
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
WO2007137303A2 (en) 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
US8466118B2 (en) 2007-04-23 2013-06-18 Saint Louis University Modulation of blood brain barrier protein expression
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
US20100160253A1 (en) 2007-05-31 2010-06-24 Glycan Biosciences Sulphated xylans for treatment or prophylaxis of respiratory diseases
CN101790385A (zh) 2007-07-12 2010-07-28 普罗森那技术公司 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子
US20100291060A1 (en) 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a
NZ585555A (en) 2008-01-07 2012-08-31 Synageva Biopharma Corp Transgenic chicken containing a transgene comprising a glycosyltransferase coding sequence
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
DK2995306T3 (en) 2009-10-19 2019-04-08 Amicus Therapeutics Inc Hitherto-unknown compositions for the prevention and / or treatment of lysosomal deposition disorders
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US20150030582A1 (en) * 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
KR101742346B1 (ko) 2010-04-23 2017-06-15 시나게바 바이오파르마, 코포레이션 리소솜 축적병 효소
AR082953A1 (es) 2010-09-09 2013-01-23 Synageva Biopharma Corp Metodos para tratar deficiencia de acido lisosomal lipasa en pacientes
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
CN103764824B (zh) 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
AU2012289916B2 (en) 2011-08-03 2017-08-03 Phoenix Tissue Repair, Inc. Collagen 7 and related methods

Also Published As

Publication number Publication date
US20170314000A1 (en) 2017-11-02
RU2012149936A (ru) 2014-05-27
MX2012012356A (es) 2013-04-11
WO2011133960A9 (en) 2013-06-13
KR20130113312A (ko) 2013-10-15
EP4241854A3 (en) 2023-11-08
US20130209436A1 (en) 2013-08-15
ES2627535T3 (es) 2017-07-28
JP6496690B2 (ja) 2019-04-03
DK2561069T3 (en) 2017-05-01
JP5925187B2 (ja) 2016-05-25
CN105214076B (zh) 2020-03-31
HK1219655A1 (zh) 2017-04-13
US20200063113A1 (en) 2020-02-27
EP4241854A2 (en) 2023-09-13
PL3205351T3 (pl) 2023-08-28
RU2017105260A (ru) 2018-08-17
SI3205351T1 (sl) 2023-09-29
US10858638B2 (en) 2020-12-08
BR112012027143B1 (pt) 2020-02-11
HUE062163T2 (hu) 2023-09-28
CA2995446A1 (en) 2011-10-27
CN102985538B (zh) 2015-09-09
HK1183059A1 (en) 2013-12-13
PT3205351T (pt) 2023-06-28
CN102985538A (zh) 2013-03-20
CA2796607A1 (en) 2011-10-27
PT2561069T (pt) 2017-05-22
AU2011242461B2 (en) 2015-10-01
AU2011242461A1 (en) 2012-11-15
JP6212081B2 (ja) 2017-10-11
KR101742346B1 (ko) 2017-06-15
RU2017105260A3 (pt) 2020-06-15
IL222513A0 (en) 2012-12-31
US20210171922A1 (en) 2021-06-10
WO2011133960A2 (en) 2011-10-27
EP3205351B1 (en) 2023-04-12
JP2013526856A (ja) 2013-06-27
US10407671B2 (en) 2019-09-10
IL252115B (en) 2019-11-28
EP3205351A1 (en) 2017-08-16
RU2741116C2 (ru) 2021-01-22
DK3205351T3 (da) 2023-06-19
EP2561069A2 (en) 2013-02-27
ES2950358T3 (es) 2023-10-09
BR112012027143A8 (pt) 2017-09-19
MX338426B (es) 2016-04-15
HUE033217T2 (hu) 2017-11-28
LT3205351T (lt) 2023-07-25
JP2016190867A (ja) 2016-11-10
CA2796607C (en) 2019-09-10
US11560554B2 (en) 2023-01-24
CA2995446C (en) 2020-05-12
EP2561069A4 (en) 2014-03-26
JP2018100289A (ja) 2018-06-28
PL2561069T3 (pl) 2017-08-31
WO2011133960A3 (en) 2012-07-12
SI2561069T1 (sl) 2017-07-31
RU2015151189A (ru) 2019-01-14
CN105214076A (zh) 2016-01-06
MX362430B (es) 2019-01-17
FI3205351T3 (fi) 2023-07-06
JP2015204842A (ja) 2015-11-19
IL252115A0 (en) 2017-07-31
EP2561069B1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
BR112012027143A8 (pt) enzima da doença do armazenamento lisossomal
DOP2013000209A (es) Inhibidores de glucosilceramida sintasa
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
BRPI0910457A2 (pt) variante de fitase, ácido nucléico, vetor, célula hospedeira, método de produção de uma variante de fitase, composição enzimática, usos, método para a produção de um alimento ou ração para animal e respectivos alimento ou composição de ração para animal e método de redução dos níveis de redução de fósforo em estrume animal
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
MX2019010226A (es) Composiciones de nanoparticulas lipidicas y metodos para administracion de arnm.
BR112013027963A2 (pt) "variante de subtilisina com atividade proteolítica, ácido nucleico, vetor de expressão, célula hospedeira, composição e método de limpeza".
BR112013010551A8 (pt) variantes de isopreno sintase para produção aprimorada de isopreno
BR112012033214A2 (pt) método e composições para distribuição no snc de iduronato-2-sulfatase
BR112012020277A2 (pt) "enzimas celulase otimizadas".
WO2012145729A3 (en) Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity
BRPI0911511B8 (pt) formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
BR112016011096A2 (pt) Aplicação de laminina à cultura de célula endotelial da córnea
BR112015009201A2 (pt) composição compreendeendo um polipeptídeo recombinante, ácido nucleico codificando o mesmo, célula hospedeira, bem como métodos para produzir uma beta-glucosidase e para hidrolisar um substrato de biomassa lignocelulósica
BR112015005782A2 (pt) variantes de enzima com propriedades aprimoradas de éster-sintase
BR112013003471A2 (pt) solução de testosterona, e, método para tratar deficiência de testosterona
BR112012005837A8 (pt) Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática
BR112014010053A2 (pt) variantes de isopreno sintase com solubilidade aprimorada para produção de isopreno
BRPI0908567A2 (pt) sequência de ácido nucleico, proteína, método para a produção de ácido itacônico em um microorganismo, célula hospedeira, usos de uma proteína e da combinação de proteína com a enzima cad e/ou uma proteína trasportadora de di/tricarboxilato da mitocôndria
BR112015004965A2 (pt) silenciamento de gene transcricional de endogenes em plantas
BR112015024118A2 (pt) protease aspártica vegetal, método de tratamento médico, utilização de uma protease aspártica vegetal, método cosmético para melhorar o aspeto da pele, protease aspártica vegetal cardosina isolada, composição, método para produzir uma protease aspártica vegetal, vetor, célula, célula com um genoma modificado, método de promover a acumulação de um polipeptídeo de interesse no vacúolo de uma célula, e, ácido nucleico
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
BRPI1007269A2 (pt) métodos para produzir um polipeptídeo, polipeptídeo, dna, cassete de expressão, célula hospedeira não humana, organismo transformado, métodos para reconhecer seletivamente um par de bases em uma sequência de dna, e para modular expressão de um gene alvo em uma célula, vetor, e , método para produzir um dna.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA LLC (US)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMACEUTICALS, INC. (US)